POPULARITY
Categories
103 episodes with annual meetings
111 episodes with annual meetings
87 episodes with annual meetings
85 episodes with annual meetings
54 episodes with annual meetings
66 episodes with annual meetings
56 episodes with annual meetings
53 episodes with annual meetings
49 episodes with annual meetings
38 episodes with annual meetings
39 episodes with annual meetings
25 episodes with annual meetings
29 episodes with annual meetings
56 episodes with annual meetings
29 episodes with annual meetings
19 episodes with annual meetings
23 episodes with annual meetings
26 episodes with annual meetings
23 episodes with annual meetings
37 episodes with annual meetings
25 episodes with annual meetings
30 episodes with annual meetings
19 episodes with annual meetings
14 episodes with annual meetings
17 episodes with annual meetings
13 episodes with annual meetings
16 episodes with annual meetings
16 episodes with annual meetings
15 episodes with annual meetings
15 episodes with annual meetings
13 episodes with annual meetings
14 episodes with annual meetings
16 episodes with annual meetings
11 episodes with annual meetings
10 episodes with annual meetings
11 episodes with annual meetings
19 episodes with annual meetings
15 episodes with annual meetings
11 episodes with annual meetings
13 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
17 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
14 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
8 episodes with annual meetings
14 episodes with annual meetings
12 episodes with annual meetings
7 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
11 episodes with annual meetings
14 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
9 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
13 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
14 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
10 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
20 episodes with annual meetings
3 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
7 episodes with annual meetings
2 episodes with annual meetings
6 episodes with annual meetings
2 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
10 episodes with annual meetings
3 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
9 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
12 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
10 episodes with annual meetings
2 episodes with annual meetings
4 episodes with annual meetings
60 episodes with annual meetings
3 episodes with annual meetings
Dr. Monty Pal and Dr. Pauline Funchain discuss the latest efforts to diagnose, prevent, and treat the series of immune-related adverse events that have emerged in the era of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Monty Pal, a medical oncologist, professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles, California. Now, it is probably no surprise to this audience that immunotherapy has transformed the treatment landscape for multiple cancer types. It remains a pillar of modern oncology. Having said that, I think we have all been baffled by certain toxicities that we run into in the clinic. Today, I am delighted to be joined by Dr Pauline Funchain to discuss some of the checkpoint inhibitor toxicities that people struggle with most. And we will also touch on some side effects of immunotherapy beyond checkpoint inhibitors: CAR-T cells, bispecifics, so on and so forth. Dr Funchain is a dear friend, and she is an associate professor and associate director of cancer research training and education at the Stanford Cancer Institute. She is co-director of the Immunotherapy Toxicity Program and the Skin Cancer Genomics Program at Stanford, where she also serves as associate program director of hematology and oncology fellowship. Dr. Funchain is also the co-founder of ASPIRE, and we are going to talk about that a little bit today, the Alliance for the Support and Prevention of Immune-Related Events. FYI for listeners, if you are interested in our disclosures, they are available at the transcript of this episode. Pauline, thanks so much for joining us today. Dr. Pauline Funchain: Monty, thank you for this invitation. It is always great to talk. Dr. Monty Pal: So, for the audience, Pauline and I know each other from my days as a fellow at City of Hope. She was a resident at Harbor UCLA and a stellar resident at that. It has just been amazing to sort of see your career grow and blossom and to witness all the cool things that you are doing. ASPIRE, in particular, sort of caught my eye. So again, for listeners, this is the Alliance for the Support and Prevention of Immune-Related Events. Can you tell us a little bit briefly about the genesis of that, how that came about? Dr. Pauline Funchain: So, there was a bunch of us who were really struggling, I mean, all of us have struggled with these immune-related adverse events, these irAEs. You know, they are new disease states, and even though they look like autoimmune diseases, they tend to need a whole lot more steroid than autoimmune diseases do and they do not totally present in the same way. And in fact, you know, Triple-M, or Triple-M overlap syndrome, is a completely new irAE, a new immune state that we have never had before the advent of checkpoint inhibitor. And so a Triple-M, for those of you who are not as familiar, that is the constellation of myocarditis, myositis, and myasthenia gravis, something that never occurs as a natural autoimmune disease. So we were starting to realize that there were some major differences with these irAEs and autoimmune diseases. We could not treat them the right way. We really needed to learn more about them. And a bunch of us who had interest in this said, "Look, we really need to be all in one space to talk about what we are doing," because all of our treatments were our own little homegrown brews, and we needed to really get together and understand how to treat these things, how to diagnose them, and then learn more about them. So, Dr. Alexa Meara from Ohio State, Dr. Kerry Reynolds from Mass Gen, we put together this research consortium, brought together all of our irAE friends, got our best subspecialists together in a research consortium, which is now only about a year and a half old. And we made this research consortium, the Alliance for Support of Prevention of Immune-Related Events, and we reached out to ASCO, and ASCO was so kind to grant us a [Alliance for Support and Prevention of Immune-Related adverse Events (ASPIRE)] Community of Practice. So we met for the first time as a Community of Practice at the ASCO Annual Meeting just this past June and really got an ASCO community together to really think about how to again, diagnose, prevent, treat irAEs. Dr Monty Pal: This is interesting to me. The ASCO Community of Practice phenomenon is something that I was not super familiar with. Can you explain to our listenership what is the ASCO Community of Practice model? If you have particular interests, how do you sort of get one started? Dr Pauline Funchain: Yeah, so ASCO has an entire page on their Community of Practice. There are multiple Community of Practice groups or COPs. There are ones for Supportive Oncology and Survivorship. There is Women in Oncology. There is a group for International Medical Graduates. And there is about, I think 10 or 12 now that have a physical presence at ASCO but also a virtual presence on the ASCO Community of Practice site. So, if you were interested in any one of these, and you can see them on the ASCO Communities of Practice sites, you would ask to become a member. Once granted membership, then there is a whole webpage of postings and conversations that people can have. You can get email digests of conversations that happen on the website, and then you can anchor it with in-person participation at the Annual Meeting. Dr Monty Pal: That is awesome, and I can think of so many different foci within oncology that really sort of deserve a Community of Practice. This definitely being one of them. You know, it strikes me as being so interesting. I mean, the checkpoint inhibitors have been around for a while now. I think when you and I were in training, gosh, back then, these were just a little bit of a pipe dream, right? But having said that, I would probably say that more than half of my kidney cancer practice is either on checkpoint inhibitors, and the vast majority have been on one at some point in their past, right? With that in mind, you know, we have all treated a lot of patients with these drugs. Why is it that we still struggle to manage the toxicities? And just to take that one step further, what are some of the toxicities that, perhaps through ASPIRE or through your experience, people struggle with the most? Dr Pauline Funchain: So, I think we are still struggling with these because again, they are new disease states, right? This is what we all experienced with COVID, a brand-new virus and a brand-new syndrome. We now have 20-plus of these as irAEs. And what we have realized about them is the immune activation that happens with these is so much more than what we have seen with autoimmune diseases. So for instance, if you have a Crohn's or ulcerative colitis, you will top out at 40 to 60 milligrams of prednisone if a Crohn's flare or ulcerative colitis flare happens. But for our severe IR colitises, you know, it is at least 1 mg per kg, often goes up to 2 mg per kg. We, in some cases, have done 1 gram pulses if we are worried that somebody is going to perforate. So that was sort of like the first 5 years of treating irAE, and then now in the sort of second 5 years of treating irAE, we have realized that that is a lot of immunosuppression, and we might be able to get away with less with the newer biologics that are on board. So, we are struggling to try to get the data for some of these irAEs that we knew, we have known for a while, but to try to get newer treatments that may immunosuppress less so that you may still be able to retain that tumor response. And in fact, some of the preclinical studies suggest that some of these biologics may actually synergize with the immunotherapy and actually make the immunotherapy more effective from a tumor perspective and calm down the irAE as sort of the bystander effect. So we are still trying to optimize those. Getting up trials in the space has been very difficult. That is one of the reasons for the genesis of ASPIRE because we realized we needed to band together to have a bigger voice in that realm. Then there are other things that are brand new. So we talked about Triple-M. So Triple-M, again, with Triple-M or any myocarditis or myasthenia, I mean, there is about a 50% chance of death from irAE based on the literature. I think we are getting better at recognizing this, and so at Stanford we have some data to say that if you serially follow troponin, that maybe your outcomes are better. You can potentially lower the percentage of cases that are fatal because you can catch them early. I mean, this is all preliminary data, but again, these are all things that are evolving, and we do not all have the right answer. I mean, even the serial troponin thing, I think, is pretty controversial. And in fact, at one of our quarterly Zoom meetings that we are doing in ASPIRE in December is going to sort of flush out that controversy about serial troponin measuring and what is the best thing to use? Would you use something like abatacept or would you use ruxolitinib? Which one is better? I think there is a lot of controversy still about these things. Dr Monty Pal: You have really piqued my curiosity here because you think about the cons of treating irAEs, right? And I worry exactly about what you had mentioned, right, which is, "Gosh, what is going on with this tumor in terms of immunosuppression?" But you think about some of the newer agents, you mentioned ruxolitinib, I have heard of dasatinib, for instance, in this setting. Frankly speaking, a lot of these, as you point out, are really thought of as being also anticancer drugs. So you have really got me thinking about the potential synergy between perhaps suppressing an irAE and augmenting antitumor activity, which I think is very interesting. Am I on the right track with that? Dr Pauline Funchain: I think so, but you will find that a lot of people will not even go there because they are worried about how much immunosuppression you are going to cause. I am at heart a geneticist, but I think an immunologist will happily tell you that the immune system is very complex. There are multiple pathways, and these drugs do not all target the same immune pathways. So if we understand a little bit more about the pathways we are targeting and pick apart the pathways that are really, really tumor relevant and the other pathways that are not tumor relevant, you may be able to piece together a better marriage of tumor response and irAE control. Dr Monty Pal: Kind of on this topic, and again, leaning on your background in genetics, where are we in terms of predicting these irAEs? I mean, you would think the holy grail would be picking out a snip or something of this for it, right, that could potentially identify that patient who is going to get Triple-M or, you know, at the very least a significant high-grade irAE event. Are we anywhere closer to that in 2025? Dr Pauline Funchain: There have been data published. There have been some big GWAS studies. All of the effect sizes are pretty small. So there are some prediction algorithms, but none of them are clinically useful. And I think when you look at the odds ratios, they will increase risk by maybe 20%. I think one of the things that we found in a very small series and supported anecdotally is something as easy as family history of autoimmune disease is probably more predictive at this point than any of those types of markers. I think we will get there, but we are not anywhere near where we would like to be. Things like TMB also, actually, there is some good data about higher TMB, higher risk of irAE too. Dr Monty Pal: Interesting. I see all this data coming through, IL-8 polymorphisms, etc. And I just wondered if any of that was ready for prime time. But I mean, this is a good message for the practicing clinician. Sounds like we are not quite there yet. And I could probably keep you on for another entire podcast to talk about this topic, but let us see if we can at least skim the surface. I never thought I would see the day when BiTEs and CAR-Ts were entering into my kidney cancer practice, but in fact, it is really become central to a lot of our clinical trials in RCC these days. I would be lying if I did not say that I was not struggling with the toxicities and so forth associated with these drugs. Can you give us a quick primer, maybe just good resources that people can go to for managing toxicity with BiTEs and with CAR and with some of these novel therapeutic modalities that we are using in the oncology clinics? Dr Pauline Funchain: I know there is a recently published toxicity manual for BiTEs in hematologic malignancies, I think it was in Blood. CAR-T is covered in many irAE guidelines. So ASCO guidelines actually has a CAR-T [cell therapy guideline], and I would be remiss not to point out that actually ASCO has a, I am a little biased, but a wonderful guideline on irAE that is actually being updated as we speak. We are hoping for publication next year. I find the format of that, there are many guidelines out there, actually. There is ASCO, SITC, ESMO has a guideline for irAE, but I find the formatting of the ASCO guideline to be much easier to flip through during clinic, just because of the visual format of the tables. But that is going to be updated next year. And with CAR-T, there is now multiple publications also in terms of guidelines. But what I will say about bispecifics and CAR-T, so they have very similar toxicities in terms of the cytokine release and also with the ICANS, so the neurotoxicity. But what we have been finding that is really interesting with BiTEs and CAR-T, and actually even with TIL, cytokine release is very similar to some of the IL-2 toxicities but not identical that we see with TIL treatment. But now we are starting to see overlap. So patients who have been treated with immunotherapy and then go on to get a bispecific or then go on to get TIL, so I have seen some colitises that have occurred after the fact. Some of the newer CAR-Ts without checkpoint have been causing some really interesting, probably not in a good way, but interesting biologically, colitises that are really refractory. So we are starting to see some overlap, and again, I think this field is just evolving constantly. Dr Monty Pal: Yeah, no, I almost think I need to go back to that fellowship that you and I did together 20 years ago and, you know, and see if I could repeat some coursework on CAR-T management. You know, Pauline, I could probably keep you on the horn for hours, but this has just been terrific. Thank you so much for sharing all of your insights with us today on the ASCO Daily News Podcast. Dr Pauline Funchain: Thank you for the invitation. It was wonderful to talk about this, and it was wonderful to catch up a little bit, Monty. Dr Monty Pal: Same here, same here. And thanks to our listeners too. If you value the insights you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Monty Pal @montypal Dr. Pauline Funchain @FunchainMD Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Monty Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Pauline Funchain: Consulting or Advisory Role: Merck, Replimune, Sanofi/Regeneron, Immunocore, Tempus Research Funding (Inst.): Pfizer, Bristol-Myers Squibb, IDEAYA Biosciences, Linnaeus Therapeutics Travel, Accommodations, Expenses: Merck
Join host Dr. Michael Blankstein as he chats with new OTA members Drs. Justin Hellwinkle and Mariel Rickert about their experiences at the Annual Meeting. For additional educational resources visit OTA.org
This week on Taking The Pulse, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Sophia McLeod, Advocacy Advisor at ACRO, or the Association of Clinical Research Organizations. Sophia shares how ACRO is working with Congress and the FDA to shape the future of clinical trials, advocating for safe, ethical, and high-quality research so patients can benefit from new treatment and therapies. We explore the challenges of regulatory uncertainty, the importance of trust and transparency in AI adoption, and how ACRO's member organizations are already using AI to accelerate patient recruitment and improve trial outcomes. Listen now!
Kathy Roe, Managing Attorney, Health Law Consultancy, speaks with Annie Shieh and Judith Waltz, Partner, Foley & Lardner, about the impact of recent changes to Medicare Advantage (MA) compliance on plans and providers. They discuss what plans and providers are responsible for when it comes to MA compliance, the current MA landscape, MA compliance changes from a plans perspective (including the current Administration and the 2026 Final Rule), MA compliance changes from a provider perspective (including the 60-day refund rule and recent litigation), and administrative enforcement actions. Annie and Judith spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA. From AHLA's Payers, Plans, and Managed Care Practice Group.Watch this episode: https://www.youtube.com/watch?v=vjRzb0UiNuYLearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Learn more about AHLA's 2025 Annual Meeting eProgram: https://educate.americanhealthlaw.org/local/catalog/view/product.php?productid=1472 Learn more about AHLA's Payers, Plans, and Managed Care Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/payers-plans-and-managed-careEssential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
The Polish American Council of Texas (PACT) will hold its annual meeting on Saturday, Nov. 15, at the Polish Heritage Center in Panna Maria. The meeting will begin after a welcome reception at 9 a.m. and will include Polish traditions, dancing by the Wawel Dance Group, a silent auction, music, tours, and a barbecue lunch. The Panna Maria Historical Society will offer tours of the Panna Maria Museum and School, and the Polish Heritage Center will be open for tours. The day's activities will conclude with a Mass at 4:30 p.m. in the Church of the Immaculate Conception of the...Article Link
How does the superpower rivalry between the US and China dictate international relations more broadly? And what does it mean for the future of trade, security and development? How does the superpower rivalry between the US and China dictate international relations more broadly? And what does it mean for the future of trade, security and development? Lynn Kuok, Lee Kuan Yew chair in South-East Asia Studies at the Brookings Institution, analyses the state of global relations almost a year into the second Donald Trump presidency. This episode is a collaboration between Beyond the Headlines and Radio Davos, a podcast from the World Economic Forum that looks at how the world is confronting its biggest challenges. It was recorded at the forum's Annual Meetings of the Global Future Councils and Cybersecurity in Dubai on October 15. , analyses the state of global relations almost a year into the second Donald Trump presidency. This episode is a collaboration between Beyond the Headlines and Radio Davos, a podcast from the World Economic Forum that looks at how the world is confronting its biggest challenges. It was recorded at the forum's Annual Meetings of the Global Future Councils and Cybersecurity in Dubai on October 15.
PCICS NewsTalk - The 2025 PCICS Annual Meeting Recap - Join a live unfiltered recording of the NewsTalk team and special guests as they discuss and recap the 2025 PCICS Annual Meeting in Austin, TX. Guests: Jill Zender (Children's Health), Carly Scahill (Children's Hospital Colorado), Amy Hemingway (Dell Children's), Saidie Rodriguez (Children's Healthcare of Atlanta), Kim DiMaria (Rocky Mountain Children's Hospital). Host/Editor/Producer: David Werho (Rady Children's Health)
How does the superpower rivalry between the US and China dictate international relations more broadly? And what does it mean for the future of trade, security and development? Lyunn Kuok, Lee Kuan Yew, Chair in Southeast Asia Studies at the Brookings Institution, and a member of the Forum's Global Future Council on Geopolitics, analyses the state of the global relations almost a year into the second Donald Trump presidency. This episode is a collaboration between the World Economic Forum's weekly Radio Davos and Beyond the Headlines, the flagship current affairs podcast of The National, the Middle East's leading English-language newspaper. It was recorded at the Forum's Annual Meetings of the Global Future Councils and Cybersecurity in Dubai on 15 October, 2025. It is co-hosted by Mina Al-Oraibi, The National's Editor-in-Chief. Watch a video version of this podcast on our YouTube channel: https://wef.ch/43bySEO Links: Network of Global Future Councils: https://initiatives.weforum.org/global-future-council Global Future Council on Geopolitics: https://initiatives.weforum.org/global-future-council-on-geopolitics Annual Meetings of the Global Future Councils and Cybersecurity 2025: https://www.weforum.org/meetings/annual-meetings-of-the-global-future-councils-and-cybersecurity-2025/ The National: https://www.thenationalnews.com/ Related podcasts: Beyond the Headlines podcast: https://www.thenationalnews.com/podcasts/beyond-the-headlines/ Related Radio Davos episodes: We have entered the age of "persistent disruption" - Visa's Wayne Best on the Chief Economists Outlook: https://www.weforum.org/podcasts/radio-davos/episodes/chief-economists-outlook-visa-wayne-best/ "New era, new mood, new challenges" - historian Adam Tooze on why things will never be the same again: https://www.weforum.org/podcasts/radio-davos/episodes/adam-tooze-cnbc-china-us-history/ Check out all World Economic Forum podcasts on wef.ch/podcasts: YouTube: - https://www.youtube.com/@wef/podcasts Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552 Join the World Economic Forum Podcast Club: https://www.facebook.com/groups/wefpodcastclub
Die 23, 42 oder doch die 76 – welches Gericht nehme ich denn nun? Das fragt sich Isa oft, wenn sie essen geht. Eine Neurowissenschaftlerin hat erforscht, welche Prozesse im Hirn bei Entscheidungen ablaufen. Eine Trainerin gibt Entscheidungstipps.**********Ihr hört: Gesprächspartnerin: Isa, fällt es schwer, sich im Restaurant zu entscheiden Gesprächspartnerin: Mona Garvert, Juniorprofessorin für Neurowissenschaften an der Uni Würzburg, forscht zu Entscheidungen Gesprächspartnerin: Christine Flaßbeck, Coach und Trainerin für Entscheidungsfragen, Professorin für Kommunikationspsychologie Autor und Host: Przemek Żuk Redaktion: Anna Maibaum, Anne Bohlmann, Friederike Seeger Produktion: Oskar Kühl**********Quellen:Demircan, C., Pettini, L., Saanum, T. et al. (2022). Decision-making with naturalistic options. Proceedings of the Annual Meeting of the Cognitive Science Society, 44(44).Nitsch A., Garvert M.M., Bellmund J.L.S. et al. (2024). Grid-like entorhinal representation of an abstract value space during prospective decision making. Nature Communications 15, S. 1198.Deseniss, A., Stahl, H. (2023). Wirksam Entscheiden. In: Stahl, H., Linden, E., Hinterhuber, H., Pircher-Friedrich, A. (Hg.) Servant Leadership. Fokus Management und Führung, vol 3. Erich Schmidt Verlag GmbH & Co. KG, Berlin.**********Mehr zum Thema bei Deutschlandfunk Nova:Bauch oder Kopf: Wie entscheiden wir uns richtig?Entscheiden: Was bei Angst vor Fehlentscheidungen helfen kannEntscheidungen - Nicht allein eine gute Wahl ist wichtig**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Meldet euch!Ihr könnt das Team von Facts & Feelings über Whatsapp erreichen.Uns interessiert: Was beschäftigt euch? Habt ihr ein Thema, über das wir unbedingt in der Sendung und im Podcast sprechen sollen?Schickt uns eine Sprachnachricht oder schreibt uns per 0160-91360852 oder an factsundfeelings@deutschlandradio.de.Wichtig: Wenn ihr diese Nummer speichert und uns eine Nachricht schickt, akzeptiert ihr unsere Regeln zum Datenschutz und bei Whatsapp die Datenschutzrichtlinien von Whatsapp.
In this episode of the American Shoulder and Elbow Surgeons Podcast, hosts Dr. Peter Chalmers and Dr. Brian Waterman are in San Diego at the 2025 ASES Annual Meeting. Author: Dr. Christopher Joyce Guest Host: Dr. Sara Edwards Topic: Do wound protectors prevent bacterial colonization during total shoulder arthroplasty? a randomized controlled trial. Author: Dr. Zaamin B. Hussain Guest Host: Dr. Uma Srikumaran Topic: Bone or metal to reconstruct the proximal humerus? An analysis of functional outcomes, complications and survival between Reverse Allograft Prosthetic Composite and Endoprosthesis Author: Dr. Dane Salazar Guest Host: Dr. Richard Friedman Topic: Standard vs. Retentive Polyethylene Liner in RTSA: An Intercompany Product Comparison
In the 1960s, John Lewis led the Student Non-violent Coordinating Committee, committed to the belief, as the New York Times put it, "that allowing himself to be beaten nearly to death in public would hasten the collapse of Southern apartheid." Which is more or less what happened, most notably at Bloody Sunday.rnrnJohn Lewis would go on to lose leadership of SNCC and decades later win election to Congress, representing Georgia from 1987 until his death in 2020.rnrnIn a moment in which our nation seems defined by both national politics and the activism those politics provoke, Congressman Lewis' life offers a model of resistance, optimism, and leadership, one that ultimately changed our nation for the better.rnrnAs part of the City Club's 2025 Annual Meeting, join us as Thompson Hine's Robyn Minter Smyers leads a conversation with biographer David Greenberg on John Lewis's remarkable life and the lessons it holds for all of us.
As the World Bank Group launches AgriConnect, a bold effort to transform smallholder farming, we explore what it means for the future of food and jobs. From the Annual Meetings in Washington, D.C. to farms in Tanzania, this episode follows how global partnerships and private sector innovation are helping farmers grow stronger businesses, create jobs, and build a more food-secure world.
Our lead story: chiefs at the recent annual general assembly of the Federation of Sovereign Indigenous Nations vote to omit discussion of a controversial forensic audit from its agenda.
In an exclusive interview hosted by Landry Signé, Anna Bjerde, the World Bank's managing director of operations, discusses the Bank's top priorities and challenges in achieving its mandate in a changing world. This interview was recorded on-site on Day One of the World Bank and International Monetary Fund's 2025 Annual Meetings in Washington, D.C. This is the final episode of season four of Foresight Africa podcast. Show notes and transcript Foresight Africa podcast is part of the Brookings Podcast Network. Subscribe and listen on Apple, Spotify, Afripods, and wherever you listen to podcasts. Send feedback email to podcasts@brookings.edu.
Our show today is being sponsored by Free Float Analytics, the only platform measuring board power, connections, and performance for FREE.DAMIONAmazon to announce largest layoffs in company history, in AI push. WHO DO YOU BLAME?Former CEO Jeff BezosAICovid (This wave of layoffs results from overhiring during the pandemic)Executive Chair and largest shareholder Jeff BezosF5 Expects Revenue Hit From Cyber Attack. F5, a $20B billion technology company with impressive gross profit margins of 81%, experienced a cybersecurity incident involving unauthorized access to certain company systems by a sophisticated nation-state threat actor. WHO DO YOU BLAME?The Risk committee: Dreyer, Klein, Montoya, Budnik*Chair Marianne Budnik is deemed to have Cybersecurity experience because she serves as a Chief Marketing Officer in the cybersecurity industryPeter Klein was the CFO at Microsoft for less than 4 years, then was the CFO for WME for 6 months and then has only been a director since 2014.Risk committee member Michael Montoya specifically. F5 revealed that the director mysteriously resigned in the same filing it disclosed the cyberattack, despite having served for only 4 years. According to the proxy, had “extensive experience as an information security executive.” Following his resignation from the Board, Mr. Montoya continued his service with the Company and has been appointed as F5's Chief Technology Operations Officer.The entire board, for doing dumb modern day board things: announced that CEO François Locoh-Donou, would assume the additional role of Chair of the Board following the Company's next Annual Meeting of Shareholders 12 days after they announced the cyberattack.Investors. 98% YES average this year: 7 over 99.2%, including Risk Committee Chair Marriane Budnik with 99.6%. Nobody feels like they have to work hard to impress anyoneF5! It's a god damn cybersecurity company!How climate change is fueling Hurricane Melissa's ferocity. WHO DO YOU BLAME?Exxon CEO Darren Woods because he sued his own shareholders last year: Arjuna Capital, LLC and Follow ThisExxon CEO Darren Woods because just yesterday: Exxon sues California over new laws requiring corporate climate disclosuresExxon CEO Darren Woods because gas and oilClimate ChangeOpenAI says U.S. needs more power to stay ahead of China in AI: ‘Electrons are the new oil' WHO DO YOU BLAME?The fear-and-spending geniuses behind the original Cold War: Truman, Stalin, ChurchillPeople who historically ignored Eisenhower and his statements on the U.S. military-industrial complex when he explicitly warned that defense contractors and the military could exert undue influence on government policy. Sound familiar?Anyone who empowered the board to not be empowered when they tried to fire Sam Altman for such reasons as:Conflicts over OpenAI's rapid growth and direction, especially the tension between aggressive AI deployment vs. safety oversight.Power dynamics between Altman, key researchers, and board members — some may have felt he had too much unilateral control.The college that let Sam Altman drop outSammy Altman Citi's Jane Fraser consolidates power with board chair vote — and a $25 million-plus bonus to boot. WHO DO YOU BLAME?The entire Compensation, Performance Management and Culture CommitteeThese two long-tenured Compensation, Performance Management and Culture Committee membersDiana L. Taylor* 10 other directorships: Brookfield Corporation, Accion (Chair), Columbia Business School (Board of Overseers),Friends of Hudson River Park (Chair), Mailman School of Public Health (Board of Overseers), The Economic Club of New York (Member), Council on Foreign Relations (Member), Hot Bread Kitchen (Board Chair), Cold Spring Harbor Lab (Member), and New York City Ballet (Board Chair)Peter B. Henry*8 other directorships: Nike, Inc., Analog Devices, Inc., National Bureau of Economic Research (Board), The Economic Club of New York (Board), Protiviti (Advisory Board), Biospring Partners (Advisory Board), Makena Capital (Advisory Board), and Two Bridges Football Club (Board)The lowest common denominator effect of bank compensation committees:Wells Fargo CEO Charlie Scharf: ~$30M special equity grant tied to becoming Chair as well as CEO (3 months after meeting)Goldman Sachs: CEO David Solomon & COO John Waldron ~$80M each (retention RSUs vesting in ~5 yrs)KeyCorp: CEO Chris Gorman & four other senior execs: ~$8M for Gorman; ~$17M combined for the five NEOsThe passive ownership (re: management-friendly) of BlackRock, State Street, and Vanguard (combined 22%): without their votes at Goldman then Say on Pay was nearly tied, which might have dissuaded the year of one-off bonuses for banking CEOs??The world is about $4.5 trillion short of securing a sustainable food supply for the future, global food and ag business CEO [Sunny Verghese, CEO of food and ag company Olam Group] says. WHO DO YOU BLAME?The world's top 28 richest people (those worth ~$160 B each) together would equal $4.5 trillionThe world's greatest sycophant Tesla chair RobynDenholm: “On the pay package specifically: “It's not about the money for him. If there had been a way of delivering voting rights that didn't necessarily deliver dollars, that would have been an interesting proposition.”Any two of these basically redundant techbro companies' market caps would sufficeNvidia ~$4.2 trillion Microsoft ~$3.8 trillion Apple ~$3.1 trillion Amazon ~$2.4 trillion Alphabet ~$2.2 trillion Meta Platforms ~$1.8 trillion Broadcom ~$1.3 trillion Taiwan Semiconductor Manufacturing Company ~$1.2 trillionBill Ackman. Because he's a douche.MATTTarget is eliminating 1,800 roles as new CEO Michael Fiddelke gets set to take over the struggling retailer - WHO DO YOU BLAME?Current CEO Brian Cornell, who's “stepping down” to the role of Executive Chair - which is basically still CEO, just on the board and doesn't have to talk to employees anymore, so he can eliminate 1800 jobs and then fade away into a multimillion dollar unaccountable board roleFuture CEO Michael Fiddelke, who starts February 1, 2026, but is current COO and was forced to send the memo to employees telling them 8% of the workforce will be cutMonica Lozano, chair of the compensation and human capital management committee of the board, who's also on the BofA and Apple boards and is the most connected board member at a highly connected board - does the chair of the human capital committee have to weigh in on firing?OpenAI - the memo makes zero mention of the fact that part of Target's problem is that it shit on gays and blacks because of a feckless internet toad named Robby Starbuck, but feels very written by AI which would account for phrases like:“Adjusting our structure is one part of the work ahead of us. It will also require new behaviors and sharper priorities that strengthen our retail leadership in style and design and enable faster execution so we can: Lead with merchandising authority; Elevate the guest experience with every interaction; and Accelerate technology to enable our team and delight our guests.”Does anyone know what that word salad actually means? Doesn't it just mean “you're fired because we basically sucked at our jobs”?Hormel recalls 4.9M pounds of chicken possibly 'contaminated with pieces of metal' - WHO DO YOU BLAME?The audit committee, the closest committee responsible for enterprise risk (ie, metal in chicken) - Stephen M. Lacy, William A. Newlands (also lead director), Debbra L. Schoneman, Sally J. Smith (chair), Steven A. White, Michael P. ZechmeisterThe governance committee - James Snee, the now retired CEO who retired somehow in January but the company still hasn't found a permanent replacement 9 months later - so they're being run by Jeff Ettinger, interim CEO? Chair Gary C. Bhojwani, Elsa A. Murano, Ph.D., William A. Newlands (also lead director), Debbra L. Schoneman, Steven A. WhiteThe one black guy on the board - Steve White - who works at Comcast, is somehow qualified to be on Hormel board, and is on BOTH the audit committee AND governance committeeThe conveyor belt that spit pieces of metal as large as 17mm long into “fire braised chicken” sent to hotels and restaurantsCervoMed appoints McKinsey veteran David Quigley to board of directors - WHO DO YOU BLAME? Board is 2 VCs, a longtime biotech CFO, and five MD/PhDs. And among those 8, there are just two woman - the co-founder/wife of the CEO and a VC. And when they did their search, they could only find a longtime professional opinion haver - a consultant from the big three?Nominating committee for lack of imaginationEx or current McKinsey, Bain, and BCG employed directors - the opinion industrial complex - make up a whopping 4% of ALL US DIRECTORSAmong boards with MULTIPLE ex opinion directors: Kohl's is 25% consultantStarbucks is 27% consultantDisney is 30% consultantsWilliams-Sonoma is 38% consultantCBRE is 40% consultant!Nominating committee chair Jane Hollingsworth, for not looking around the room and saying, “hey dudes, can we add, like, maybe, ONE other lady?”Co founders Sylvie Gregoire and John Alam (also CEO) who own 17.3% of voting power - add in Josh Boger, board chair and 12.3% voter, and you basically have the CEO daddy and his buddy Josh with 29.6% of voting controlSylvie and John's bios, which neglect to mention they're married to one anotherWe are all terrified of the future - which headline is worse for your terror? WHO DO YOU BLAME?The world is about $4.5 trillion short of securing a sustainable food supply for the future, global food and ag business CEO saysBill Gates Says Climate Change ‘Will Not Lead to Humanity's Demise' - ostensibly because billionaires in bunkers will, in fact, survive on cans of metal-filled Hormel chili.Sorry, Yoda. Mentors are going out of styleMan Alarmed to Discover His Smart Vacuum Was Broadcasting a Secret Map of His HouseJennifer Garner's baby food company is going public on the NYSE — should investors be putting their eggs in this basket?Woman Repeatedly Warned by Canadian Exchange Not to Transfer Crypto, Gets Scammed AnywayOpenAI completes restructure, solidifying Microsoft as a major shareholder - MSFT owns 27%, the non profit which controlled the company “for the benefit of humanity” now will only control it for 26% of humanity?Tesla risks losing CEO Musk if $1 trillion pay package isn't approved, board chair says - IF MUSK LEAVES, WHO DO YOU BLAME?Robyn Denholm, board chair, whose job it is to manage Musk, but does it like an overwhelmed permissive mother who parents with chocolate and Teletubbies when the kid has a tantrumKimbal Musk - I was told by a bunch of directors and institutional investors at a conference, no joke, that Kimbal was still on the board (ie, not voted out) to control his brother's ketamine intake and crazy episodes. So if he throws a tantrum and leaves, isn't it bro's fault? This is a binary trade - Musk gets extra pay/control, stock goes up and isn't de-meme'd. Musk doesn't, he leaves and the stock is de-meme'd and drops arguably by 66% or more to be more like a car company with some tech. So do we blame investors, no matter what they do? They meme'd the stock in the first place, he couldn't get a trillion extra dollars if they hadn't pumped up the stock - and now they could vote with humanity (no pay) or meme capitalism (pay)!Techbro middle school conservatism - is this Ben Shapiro and Joe Rogan's fault? A Yale economist paper suggests that Musk's politics cost between 1 and 1.26 million Tesla car sales… Would we even be worried if Musk stayed out of politics? Wouldn't the market have just paid him whatever?Pop quiz: which directors stay on the board if Musk leaves in a tantrum?Jeffrey StraubelKimbal MuskRobyn DenholmJames MurdochKathleen Wilson-ThompsonIra EhrenpreisJack HartungJoe Gebbia
Scott Strickland, Shareholder, Hall Render Killian Heath & Lyman PC, Jim Carr, Co-Founder and Partner, InHealth Advisors, and Rachel Polzin, Assistant General Counsel, SSM Health, discuss the value-based enterprise (VBE) framework and the associated exceptions and safe harbors. They cover why the uptick in the framework has been a bit slower than anticipated, ways for health care organizations to take advantage of the VBE exceptions and safe harbors to mitigate risk, the future of traditional co-management arrangements, integrating new compliance processes, and how the Transforming Episode Accountability Model might promote the adoption of VBE. Scott, Jim, and Rachel spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=VBfiNQ8_AowLearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Learn more about AHLA's 2025 Annual Meeting eProgram: https://educate.americanhealthlaw.org/local/catalog/view/product.php?productid=1472 Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
Welcome to Episode 200 of The Spokesman Speaks podcast. In this episode, we share expert tips for strengthening the communication between farmers and their landlords. Erin Herbold-Swalwell, a Farm Bureau attorney with extensive experience in farm succession and landowner relations, and Catherine DeLong, an ISU Extension professional who specializes in helping farmers and landowners discuss conservation investments, share their advice with farmers. Resources Mentioned in this Episode: Register for Iowa Farm Bureau's Annual Meeting. Visit ISU's Ag Decision Maker website. Iowa Farm Bureau's Take Root farm succession program Learn more about Iowa State University Extension's Landowner Education Program.
On this episode of Change Makers go inside the 2025 Annual Meeting held at the Louisville Marriott Downtown. For over a century, this gathering has brought together leaders, educators, and innovators in the field of blindness and low vision. You'll hear firsthand from presenters, award winners, and attendees about the highlights, breakthroughs, and moments that made this year's event unforgettable.Stick around after the recap for our monthly Tech Takeaway, where we show you how to personalize your Monarch device.On this episode (in order of appearance)Stephanie Steffer, CViConnect Gabriel Einsohn, Marketing and Product Development The Puzzled Co.Tracy Gaines, CTEBVI Executive DirectorConnie Stone, National Prison Braille Network speakerWillow Free, APH Technical Innovations Product ManagerGreg Stilson, APH Vice President of Digital TransformationDr. William Wiener, Wings of Freedom award recipientLee Nasehi, President and CEO of VisionServe AllianceIsaac Shapiro, Co-CEO and President of CleanlogicJennifer Wenzel, APH Technology Product SpecialistMichael Dennis, APH Technology Products SpecialistAdditional LinksCViConnectThe Puzzled Co. websiteMemory Puzzles: ShapesMemory Puzzles: Fruits & VeggiesMeet Your Match with Memory Puzzles: ShapesBlog - My Sight: A Hands-On Curriculum Empowering StudentsCTEBVIVisionServe AllianceCleanlogic Body CareNational Prison Braille Network
A sermon from 2 Samuel 9 delivered at the 2025 Annual Meeting of the Logan-Todd Baptist Association.Speaker: Gregory W. Mathis
This week on Taking The Pulse, Heather and Lauren record at the NCLifeSci 2025 Annual Meeting with Dr. Justin Collier, Chief Technology Officer for Healthcare at Lenovo North America. A practicing physician turned tech leader, Dr. Collier shares how AI is transforming the health care industry, from medical imaging and ambient documentation to administrative workflows and clinical efficiency. We explore the importance of governance, education, and ethical deployment of AI, and how health systems can start small to build trust and drive measurable results. Tune in for an insightful discussion on the future of healthcare!
Welcome to ACR Convergence 2025 in Chicago! Here, Dr. Hausmann delivers a quick update on what our podcasts will cover while the meeting is in session. Don't forget to tune in to ACR on Air and ACR Journals on Air each morning, starting this Saturday, to catch up on the latest in Rheumatology
Bryan Perry, Senior Managing Director, FTI Consulting, Amanda Wait, Partner and Head of Antitrust, Michael Best & Friedrich LLP, and Elizabeth Odette, Assistant Attorney General and Manager of the Antitrust Division, Office of the Minnesota Attorney General, discuss the changing landscape of antitrust scrutiny of health care transactions. They cover substantive antitrust scrutiny and the enforcement perspective, practical guidance for anticipating and planning for antitrust review processes, and tips on managing simultaneous federal and state antitrust reviews. Bryan, Amanda, and Elizabeth spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=VhSatIlqd5QLearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Learn more about AHLA's 2025 Annual Meeting eProgram: https://educate.americanhealthlaw.org/local/catalog/view/product.php?productid=1472 Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
The USEA Annual Meeting & Convention is just around the corner and this year, it's all about access, transparency, and celebration. Nicole Brown is joined by CEO Rob Burk and outgoing President Lou Leslie for a full preview of what's in store in New Orleans from December 11–14. From the first-ever “open door” format that welcomes members into nearly every meeting, to keynote speaker Natalie Hummel's work on mindset and performance, this year's convention promises to be as forward-thinking as it is fun. Expect good company, big ideas, and plenty of inspiration as the USEA community comes together to reflect, connect, and look ahead.
What happens when counterfeiting, crypto, and trademarks collide? This episode of Brand & New takes you inside the fast-moving world of Web3, where brand protection meets blockchain. Host Willard Knox chats with Moish Peltz, Co-Managing Partner at Falcon Rappaport & Berkman LLP (USA), about the opportunities, and risks, facing companies in decentralized digital spaces. In his daily practice, Mr. Peltz coordinates between the Digital Asset Practice Group and all other practice groups of the firm. He also advises numerous venture technology companies on emerging technology and blockchain matters, with a focus on the intersection of IP and blockchain. He has been advising cryptocurrency ventures since 2014 and combines his knowledge of the blockchain with a decade of IP and business law experience where he helps entrepreneurs grow their businesses and brands and resolve disputes.From NFTs to stablecoins to enforcement strategies that actually work, in this episode of Brand & New, you'll learn why blockchain is reshaping how brands defend their identities online.This episode was recorded during INTA's 2025 Annual Meeting in San Diego, California.RESOURCES: About Moish PeltzNon-Fungible Tokens (NFTs): A Report From INTA (2023)"Back to the Future with Blockchain Domain Names: Toward A Global Policy to Fight Cybersquatting in Web 3.0" (The Trademark Reporter, July 2024)
AACPDM special: Effects of Power Training combined with interval treadmill training on walking capacity versus performance in real world settings in youth with cerebral palsy.This paper is a contender for the AACPDM's highest abstract honour - the Gayle G Arnold Award - to be presented at The American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) Conference - the 79th Annual Meeting!“Celebrating Resilience” October 15-18, 2025, to be held in New Orleans, LA.
This week, we are on the ground at the World Bank-International Monetary Fund annual meetings, closely following the conversations that will shape the global development sector. As we note a reduced focus on climate change policy compared to previous years, we are tracking how the conversation is pivoting, with climate issues now being approached through an energy security angle. In addition to examining the World Bank's ongoing focus on global job creation, we highlight our exclusive on-the-sidelines interview at Devex Impact House with U.S. Rep. French Hill, a Republican from Arkansas, who shared insights on the Trump administration's “America First” approach to foreign assistance, providing a Republican perspective on U.S. engagement in global development. In order to discuss the key talking points at the annual meetings, Devex's Adva Saldinger sits down with Michael Igoe and Elissa Miolene for the latest episode of our podcast series, recorded live at Devex Impact House on the sidelines of the main summit. Sign up to the Devex Newswire and our other newsletters: https://www.devex.com/account/newsletters
This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall provides expert commentary on study design, efficacy, safety considerations, and clinical implications.Topics Covered1. SMOLDERING MULTIPLE MYELOMALINKER-SMM1Phase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration.Discussion Points:Appropriateness of 2-year treatment duration for precursor conditionEfficacy and MRD-negative ratesSafety considerations in asymptomatic populationPatient selection if available today2. NEWLY DIAGNOSED MULTIPLE MYELOMAMajesTEC-5Phase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance.Discussion Points:Post-induction MRD-negativity rates with Tec-DR and Tec-DVRGrade 3-5 infection rates and infection-related deathsQuestionable utility of bortezomib and need for ASCT with 100% MRD-negativityHigh infection prophylaxis requirementsMagnetisMM-6Phase 1/2 dose-finding study of fixed-dose elranatamab 76 mg Q4W with Dara-Len in 37 transplant-ineligible NDMM patients (median age 75 years).Discussion Points:VGPR or better ratesSafety profile including infections and CRS/ICANSRisk of continuous therapy in elderly/frail populationLINKER-MM4Phase 1/2 study of linvoseltamab monotherapy in NDMM with both transplant-eligible and transplant-ineligible pathways, exploring three dose levels (50, 100, 200 mg).Discussion Points:Efficacy of single-agent Linvo in NDMMWhether any NDMM population could achieve long-term control with single-agent BCMA BsAbSafety profile3. RELAPSED/REFRACTORY MULTIPLE MYELOMACAMMA-1Phase 1b randomized dose-expansion study of cevostamab (FcRH5×CD3 bispecific) combined with pomalidomide-dexamethasone in BCMA-naïve patients with median 2 prior lines of therapy.Discussion Points:Efficacy and safety resultsPositioning in treatment paradigmUse before BCMA BsAbs?Sonrotoclax + Dexamethasone in t(11;14) R/R MMPhase 1/2 study of sonrotoclax (next-generation BCL2 inhibitor) plus dexamethasone as an all-oral regimen in patients with t(11;14) R/R MM (median 3 prior lines, ~75% triple-exposed).Discussion Points:Efficacy including response rate and PFSSafety profileFuture of BCL2 inhibitors in t(11;14) myeloma in the era of BsAbs and CAR TRedirecTT-1Phase 2 trial combining teclistamab + talquetamab in 90 heavily pretreated patients with R/R extraosseous extramedullary disease (84% triple-class refractory, 36% penta-refractory, 20% prior BCMA CAR T).Discussion Points:Response rate and durability in difficult-to-treat populationSafety concerns with dual bispecific combinationOff-label use considerations4. CAR T-CELL THERAPY TOXICITIESCAR T Immune-Related Adverse Events (UPenn Study - Ho et al)Large cohort study of 198 patients (125 cilta-cel, 73 ide-cel) examining all adverse events other than CRS, ICANS, IEC-HS, and IECAHT.Discussion Points:Landscape of CAR T IRAEs: incidence, types, and timingRisk factors identified for CirAEsMechanism of toxicities and role of CD4+ CAR T-cellsClinical implications: Should prophylactic corticosteroids be used? What ALC threshold? Optimal dose/duration? Prospective studies needed?
Jennifer Hutchens, Partner, Dechert LLP, and Tom Spellman, Associate General Counsel and Vice President, Fresenius Medical Care, discuss how health care joint ventures can provide considerable financial, legal, and operational flexibility and opportunity for their participants, along with unique regulatory and relationship considerations. They cover when a joint venture can be useful for a health care business venture, what key financial and operational provisions to consider, and how to plan for both good and ranging business outcomes. Jennifer and Tom spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=MH9KgAduuW4Learn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
Zippy Duvall, American Farm Bureau president and farmer from Georgia talks about his upcoming visit where he'll deliver the keynote address at KFB's annual meeting Dec. 6-8 in Manhattan.
Outside of passing bread and wine, the Annual Meeting of Jehovah's Witnesses is the most important event of the year. In this installment, the Governing Body exceeds expectations by playing trivia games about them, encouraging 'free thinking,' and previewing their new video series to the masses. Birthday's are EVIDENTALLY still bad. TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast
In this episode of Current Account, Clay previews a variety of themes and topics poised to be the center of many discussions during the upcoming 2025 IIF Annual Membership Meeting and IMF/World Bank Annual Meetings. Clay breaks down the major themes from the upcoming meetings into three main categories: (1) Risks, such as geopolitical risk, policy uncertainty and the rise of global debt; (2) Opportunities, including the rise of gold, increased role of artificial intelligence and further developments in digital asset expansion and regulation; and (3) Potential Institutional Issues, highlighted by the role and demand for critical minerals, shifts in supply chains and tariff implications, a call for simplification in the realm of supervision and regulation, and region-specific issues - as recently brought to light in Argentina. Click here for more information on the 2025 IIF Annual Membership Meeting. IIF Members can watch the "Countdown to the AMM!" here. This IIF Podcast was hosted by Clay Lowery, Executive Vice President, Research and Policy, with production and research contributions from Christian Klein, Digital Graphics and Production Associate and Miranda Silverman, Senior Program Assistant.
Chuck and Chris host a live podcast in Vancouver at the ASSH Annual Meeting. Listen in for some fun and lively discussion about topics pertinent to all including dupuytrens, distal radius fractures and more!We are in need of a podcast intern! We would appreciate any referrals!See www.practicelink.com/theupperhand for more information from our partner on job search and career opportunities.The Upper Hand Podcast is sponsored by Checkpoint Surgical, a provider of innovative solutions for peripheral serve surgery. To learn more, visit https://checkpointsurgical.com/.As always, thanks to @iampetermartin for the amazing introduction and concluding music.For additional links, the catalog. Please see https://www.ortho.wustl.edu/content/Podcast-Listings/8280/The-Upper-Hand-Podcast.aspx
Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie and Dr Laurie H Sehn, moderated by Dr Abramson, including the following topics: Introduction (0:00) Integrating Bispecific Antibodies into the Management of Follicular Lymphoma (FL) — Dr Crombie (2:08) ICurrent Role of CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for FL — Dr Abramson (21:01) Other Recently Approved and Emerging Novel Therapies for Relapsed/Refractory FL — Dr Sehn (40:52) CE information and select publications
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma. CE information and select publications here.
For New Jersey Assemblyman Paul Kanitra, the past year has been nothing short of “crazy.” At ALEC's 52nd Annual Meeting in Indianapolis, he described a state budget that has expanded considerably since Governor Christie left office in 2018. Now, with a spending spree aimed at ideological projects rather than practical needs, the people of the Garden State are paying more for less. Special Guest: Paul Kanitra.
The Berrien Community Foundation has announced $270,000 in grants to community organizations throughout the county as it held its 73rd Annual Meeting and Celebration on Thursday night. More than 1,000 teachers from across Berrien County gathered at St. Joseph High School on Friday for a professional development conference partly organized by Berrien RESA. Berrien County has reached an agreement with the Southwest Michigan Regional Airport to help keep Euclid Avenue clear for traffic during the winter after an issue was brought to the county's attention by New Heights CCDA. See omnystudio.com/listener for privacy information.
In our penultimate episode, Abdul and Katelyn discuss the week's public health news, which includes: Why Democrats are demanding Republicans extend healthcare subsidies How the shutdown has impacted funding to public health programs The new childhood vaccination schedule The CDC's official approval of the Covid booster Then they look back on the last 6 years, and play some of Abdul's favorite moments from American Dissected. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Work. Science Matters.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns. APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25.
In this episode of Your Next Mission® video podcast, titled “Voice of the Army”, the 15th SMA (R) Daniel A. Dailey, the VP of NCO & Soldier Programs at the Association of the United States Army (AUSA) joins SMA Tilley for a dynamic conversation about the incredible work being done by AUSA—the Voice of the Army. As we gear up for the Annual Meeting kicking off next week, they dive into how AUSA continues to advocate for Soldiers, Families, and Army initiatives around the globe. Tune in to hear stories, insights, and why AUSA remains such a vital force in supporting and representing our Army community.
On today's Land Warfare Series program, sponsored American Rheinmetall, Dan Roper, a retired US Army colonel who is now the director of national security studies at the Association of the United States Army's Land Warfare Institute, joins Defense & Aerospace Report Editor Vago Muradian to discuss the expected messages that Army leaders will delivery at the association's annual meeting and tradeshow next week in Washington, DC; the programs the force will need to execute operations worldwide; learning the right lessons from the Ukraine war as well as from the Cold War, Afghanistan and Iraq; keys countering thoughtful and agile adversaries; novel approaches to fighting in highly contested battlefields; why size matters for military forces in an era when conflict could both erupt quickly and escalate rapidly; and why precision and good leadership are vital. Our coverage of AUSA is sponsored by Lockheed Martin.
Join us as we delve into Flint Energies' Annual Review, celebrating a year of remarkable achievements and milestones. Discover how Flint Energies has powered communities, driven innovation, and set new standards in the energy sector. From groundbreaking projects to community initiatives, this episode offers an insightful look into the successes of Flint Energies. Tune in to learn more about the impact and vision that continue to shape the energy landscape.Flint Energies Members: make sure to join us for our Annual Meeting on Tuesday, October 21, 2025, at 10:00 a.m. at our Reynolds Operations Center located at 19 Racetrack Road Reynolds, GA 31076. Doors open at 8:30 a.m. Important Links Referenced in this Episode:Learn more about our Rural Murals, Scholarships, Operation Round Up®, and Bright Ideas Teacher Grant. Sign up to participate in Operation Round Up®Read this month's issue of Georgia Magazine.Follow Flint Energies on Facebook, Follow Flint on Instagram, Follow Flint on LinkedIn. Credits: Intro and outro song "Runnin' On Sunshine" Performed by: ReveilleWritten by: Brendan St. Gelais (BMI 100%)Published by: Boss Soundstripe Productions (BMI 100%)
Leah Voigt, Chief Compliance Officer, Corewell Health, and Anthony J. Burba, Partner, Barnes & Thornburg, discuss takeaways from recent health care fraud enforcement activity, recent compliance guidance from DOJ and OIG, and practical steps that health care companies can take to address, mitigate, and remediate risks in key focus areas for the government. Anthony and Leah spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=PviibFEEEpELearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
In a precursor to the Annual Meeting, the Governing Body of Jehovah's Witnesses rolled out fellow King Priest Samuel Herd to tell millions of people about their poor baptism rates, special conventions vs. international conventions and how we should crave their spiritual food.TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast
Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma. CE information and select publications here.
Abdul and Katelyn discuss the latest news in public health, which includes: Trump's $100,000 H1-B visa fee, which is could significantly hurt staffing in rural hospitals A new 100% tariff on certain imported brand-name drugs RFK Jr's announcement that the FDA is re-evaluating the abortion medication mifepristone A new scientific breakthrough that's giving hope to people with Huntington's Disease Then Abdul sits down with Dr. Aziz Rahman, an American physician who recently completed a medical mission in Gaza. Dr. Rahman offers a gripping account of the devastation in Gaza, and the heroic efforts of doctors serving there. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Work. Science Matters.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Boll & Branch: For a limited time get 20% off your first set of sheets plus free shipping at BollAndBranch.com/AD. Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns. APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25.
Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos, Dr Hans Lee, and Dr Noopur Raje, moderated by Dr Joseph Mikhael, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Raje (3:17) Integrating Bispecific Antibodies into the Management of R/R MM — Dr Lee (20:38) Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators in Therapy for MM — Prof Dimopoulos (40:37) CE information and select publications
In this episode of the American Shoulder and Elbow Surgeons Podcast, hosts Dr. Brian Waterman and Peter Chalmers are at the SECEC Annual Meeting in Rotterdam. Author: Dr. Maxime Antoni Guest Host: Dr. Robert Gillespie Title: Functional impact and risk factors for humeral implant migration in stemless RSA Author: Dr. Bjorn Salomonsson Guest Host: Dr. Brad Schoch Title: Survival analysis of total shoulder arthroplasty for glenohumeral osteoarthritis. Comparison of anatomical and reversed implants a registry study Author: Dr. Arno Macken Title: Combining pre-operative benzoyl peroxide and subcutaneous iodine after incision is effective in reducing cutibacterium acnes presence in shoulder surgery; results of the C3PO trial. Author: Dr. Samuel Antuna Topic: Shoulder Arthroplasty: first clinical results of robotic-assisted shoulder replacements
Chuck and Chris are joined by the co-chairs of the ASSH Annual Meeting, Lindley Wall and Carl Harper. They share insights on ALL of the exciting plans for the robust annual meeting in Vancouver. Join us and get excited about the. meeting with a few insider tips.We mention a new book about Sterling Bunnell. If you are not going to the meeting and would like to purchase a copy, use this link.https://american-society-for-surgery-of-the-hand.myshopify.com/products/dr-sterling-bunnell-from-son-of-the-gold-rush-to-founding-father-of-hand-surgeryWe are in need of a podcast intern! We would appreciate any referrals!See www.practicelink.com/theupperhand for more information from our partner on job search and career opportunities.The Upper Hand Podcast is sponsored by Checkpoint Surgical, a provider of innovative solutions for peripheral serve surgery. To learn more, visit https://checkpointsurgical.com/.As always, thanks to @iampetermartin for the amazing introduction and concluding music.For additional links, the catalog. Please see https://www.ortho.wustl.edu/content/Podcast-Listings/8280/The-Upper-Hand-Podcast.aspx
Abdul begins the show with a major announcement about America Dissected. Then, he and Katelyn discuss: RFK Jr's Autism report, which points to an unproven link between autism and acetaminophen Last week's ACIP meeting, where RFK Jr's new appointees approved new recommendations on the Covid booster and MMRV vaccines The end of the Covid summer wave, and how it compared to last year Then Abdul sits down with Dr. Demetre Daskalakis, who recently resigned in protest from the FDA. They discuss the chaos at the agency and the future of public health under RFK Jr. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Matter. Science Works.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: OneSkin: Get 15% off OneSkin with the code DISSECTED at https://www.oneskin.co/ #oneskinpod Incogni: Take your personal data back with Incogni! Use code DISSECTED at the link below and get 60% off an annual plan: https://incogni.com/dissected APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25.
© 2020-2025 Ivy Podcast Discovery LLC
